While anti-portal hypertensive effects of FXR agonists have been previously observed in rodent models of non-NASH etiology [13,25,26], this is the first experimental study to demonstrate that non-steroidal FXR agonists can reduce portal hypertension in NASH cirrhosis. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.